Foresee announced the Primary Endpoint Results of FP-025 in an Allergic Asthma Phase 2a Trial

Foresee Pharmaceuticals announced the primary endpoint data of FP-025, an oral MMP-12 inhibitor, in an allergic asthma Phase 2a proof-of-concept (POC) trial, in a press conference.